Immunoassay Companies, Mergers and Acquisitions (M&A)

Top Companies in the Immunoassay Market

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson, and Company
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc.
• Siemens Healthinners
• Danaher Corporation (Beckman Coulter)
• Quidel Corporation
• Ortho Clinical Diagnostics
• Sysmex Corporation

Market Forecast

The global immunoassay market size is calculated at US$ 35.61 billion in 2024, grew to US$ 37.29 billion in 2025, and is projected to reach around US$ 56.54 billion by 2034. The market is expanding at a CAGR of 4.72% between 2025 and 2034.

What are the Key Trends in the Immunoassay Market?

Highly developed healthcare infrastructure, technological advances, and ongoing R&D investments are increasingly fueling innovations in the respective market.

• In May 2025, Aptamer Group plc partnered with Neuro-Bio Ltd for the successful adaptation of the Optimer-based test for Alzheimer’s disease into an Enzyme-Linked Immunosorbent Assay (ELISA).
• In October 2024, ADx NeuroSciences, a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a player in ultra-sensitive immunoassay technologies, collaborated for the development of tailored biomarker assay solutions using Alamar’s NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) immunoassay platform and ARGO HT System.

The Immunoassay Market Value Chain Analysis

R&D

The global market leverages the selection of appropriate, specific antibodies and antigens, optimization of the assay format, creation of a "sandwich" with a labeled secondary antibody, then validation of the assay, and, at the end, performing a quality control process, such as spike recovery, to ensure accuracy and minimize interference.

Key Players: Abbott, Thermo Fisher Scientific, and Bio-Rad Laboratories, etc.

Packaging and Serialization

The immunoassay market involves manufacturing the device (e.g., a lateral flow assay) with its components, such as the sample and conjugate pads, furthermore, the primary, secondary, and tertiary packaging, and ultimately labelling with a unique, trackable identifier (like a QR Code or DataMatrix code).

Key Players:  OPTEL, VISIOTT, Antares Vision Group, Systech,  ACG, etc.

Patient Support and Services

By collecting blood or saliva samples and testing to measure specific proteins, hormones, or antibodies, assisting in disease management from diagnosis to follow-up care across different issues, mainly infections, autoimmune disorders, cardiovascular issues, and cancers.

Key Players:  Vision Diagnostic Centre, IQVIA Labs,  bioMérieux, Meridian Bioscience, etc.

Latest Announcements by Industry Leaders

In July 2025, TrilliumBiO, a leader in biomarker discovery and precision diagnostics, announced a strategic alliance with T-NeuroDx, a pioneering diagnostics company, to advance the progression of blood-based biomarker diagnostics for Alzheimer's disease. Laura Vivian, CEO of TrilliumBiO, replied that this will leverage more accessible, non-invasive diagnostics for patients and providers.

What are the Recent Developments in the Immunoassay Market?

• In September 2025, Beckman Coulter Diagnostics, a Danaher company and a player in global clinical diagnostics innovation, unveiled the first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test.
• In April 2025, Labcorp, a global company of innovative and comprehensive laboratory services, launched its pTau-217/Beta Amyloid 42 Ratio, a prominent new blood-based biomarker test to assist in the diagnosis of Alzheimer's disease.
• In April 2025, Metrion Biosciences, a preclinical contract research organisation (CRO), launched its validated, high-throughput NaV1.9 screening assay to accelerate the discovery and development of novel pain therapeutics.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com